Geron stock trades at EUR 0.88 on Lang & Schwarz Friday

Published on 11/06/2026 at 22:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Geron stock stays in focus as the company expands RYTELO access in Europe. Geron reaffirmed its 2026 RYTELO sales outlook.

RYTELO growth meets European expansion

Geron reported third-quarter RYTELO net product revenue of USD 60.1 million.
The company expects RYTELO to become available in Germany by year-end and in France in 2027.

GERN, US3741631036, Illustration mit AI erstellt.

Geron Corporation stock traded at 0.88 euros on Lang & Schwarz at 10:38 p.m. CET on Friday, November 6, 2026. The real-time quote of Geron stock provided the latest evening reference for investors.

RYTELO growth and guidance

In a November 4 release, Geron reported third-quarter 2026 product revenue of USD 60.1 million, up from USD 47.2 million a year earlier. Net income reached USD 1.4 million, compared with a net loss of USD 18.4 million in the third quarter of 2025, according to the company.

Geron kept its 2026 RYTELO net product revenue outlook at the mid-to-high end of a USD 220 million to USD 240 million range. The company lowered its full-year operating expense outlook to USD 220 million to USD 230 million from USD 230 million to USD 240 million. The figures and guidance are detailed in the Geron Corporation release.

European rollout adds a catalyst

The company has started a gated commercial launch for RYTELO in selected European markets. Geron expects the medicine to become available in Germany later this year and in France in 2027. As of September 30, Geron reported approximately USD 339.4 million in cash, restricted cash and marketable securities.

Geron also said it discontinued the Phase 3 IMpactMF trial after an independent Data Monitoring Committee concluded that the study was unlikely to meet its overall-survival endpoint. The company reported no new safety signals that changed the known safety profile of imetelstat.